Wantai Biotech announced that the net loss attributable to the owner of the parent company from January 1, 2026 to June 30, 2026 is estimated to be 116 million yuan to 140 million yuan, and a net loss of 144 million yuan for the same period last year. During the reporting period, the company's revenue achieved relatively rapid growth. The core benefit was the continuous promotion of terminal access after the launch of the nine-valent HPV vaccine and the continuous volume of product sales, which effectively hedged the negative impact of value-added tax rate adjustments on biological products and vaccines on profits. No profit was achieved in this period, and the overall profit pressure was mainly due to the combination of multiple phased factors: first, the expansion of the nine-valent HPV vaccine marketing team and the continuous improvement of the national marketing channel and academic promotion system, which led to a significant increase in sales expenses; second, the nine-valent HPV vaccine was approved for only 18 months, and the sales window is relatively short. Some batches of inventory that were put into production in the early stages now have less than 6 months remaining until the expiration date, and the company is preparing for the inventory price drop; third, the Xiamen diagnostic base project has been converted and put into use, and depreciation of fixed assets has been added in the current period; at the same time, the company continues to maintain high investment in innovative research and development, and the company has not achieved stable profits due to multiple factors. However, compared to the same period last year, losses attributable to owners of the parent company after deducting non-recurring profits and losses have narrowed.

Wantai Biotech announced that the net loss attributable to the owner of the parent company from January 1, 2026 to June 30, 2026 is estimated to be 116 million yuan to 140 million yuan, and a net loss of 144 million yuan for the same period last year. During the reporting period, the company's revenue achieved relatively rapid growth. The core benefit was the continuous promotion of terminal access after the launch of the nine-valent HPV vaccine and the continuous volume of product sales, which effectively hedged the negative impact of value-added tax rate adjustments on biological products and vaccines on profits. No profit was achieved in this period, and the overall profit pressure was mainly due to the combination of multiple phased factors: first, the expansion of the nine-valent HPV vaccine marketing team and the continuous improvement of the national marketing channel and academic promotion system, which led to a significant increase in sales expenses; second, the nine-valent HPV vaccine was approved for only 18 months, and the sales window is relatively short. Some batches of inventory that were put into production in the early stages now have less than 6 months remaining until the expiration date, and the company is preparing for the inventory price drop; third, the Xiamen diagnostic base project has been converted and put into use, and depreciation of fixed assets has been added in the current period; at the same time, the company continues to maintain high investment in innovative research and development, and the company has not achieved stable profits due to multiple factors. However, compared to the same period last year, losses attributable to owners of the parent company after deducting non-recurring profits and losses have narrowed.